Cost-effectiveness of Favipiravir in moderately to severely ill COVID-19 patients in the real-world setting of Saudi arabian pandemic referral hospitals

• Main Authors: Ahmad Alamer (Author), Abdulaali R. Almutairi (Author), Shiraz Halloush (Author), Ahmed Al-jedai (Author), Ahmed Alrashed (Author), Mashael AlFaifi (Author), Yahya Mohzari (Author), Malak Almutairi (Author), Fatimah AlHassar (Author), Jude Howaidi (Author), Wedad Almutairi (Author), Ivo Abraham (Author), Nimer Alkhatib (Author)
• Format: Book
• Published: Elsevier, 2023-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 1319-0164; 10.1016/j.jsps.2023.02.003
• Keywords: COVID-19; Favipiravir; Real-world data; Cost-effectiveness; Saudi Arabia; Therapeutics. Pharmacology; RM1-950
• Source: Saudi Pharmaceutical Journal, Vol 31, Iss 4, Pp 510-516 (2023)

Purpose: We aimed to evaluate the cost effectiveness of Favipiravir treatment versus standard of care (SC) in moderately to severely ill COVID-19 patients from the Saudi healthcare payer perspective. Methods: We used the patient-level simulation method to simulate a cohort of 415 patients with moderate to severe COVID-19 disease who were admitted to two Saudi COVID-19 referral hospitals: 220 patients on Favipiravir and 195 patients on SC. We estimated the incremental cost-effectiveness ratio (ICER) of Favipiravir versus SC in terms of the probability to be discharged alive from hospital and the mean time in days to discharge one patient alive. The model was performed twice: first, using unweighted, and second, using weighted clinical and economic data. Weighting using the inverse weight probability method was performed to achieve balance in baseline characteristics. Results: In the unweighted model, base case (probabilistic) ICER estimates favored Favipiravir at savings of Saudi Riyal (SAR)1,611,511 (SAR1,998,948) per 1% increase in the probability of being discharged alive. As to mean time to discharging one patient alive, ICERs favored Favipiravir at savings of SAR11,498 (SAR11,125). Similar results were observed in the weighted model with savings using Favipiravir of SAR1,514,893 (SAR2,453,551) per 1% increase in the probability of being discharged alive, and savings of SAR11,989 (SAR11,277) for each day a patient is discharged alive. Conclusion: From the payer perspective, the addition of Favipiravir in moderately to severely ill COVID-19 patients was cost-savings over SC. Favipiravir was associated with a higher probability of discharging patients alive and lower daily spending on hospitalization than SC.